Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lyell Immunopharma, Inc. (LYEL : NSDQ)

• Company Description    Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 161

• Price / Volume Information    Yesterday's Closing Price: $9.39 Daily Weekly Monthly 20 Day Moving Average: 164,638 shares Shares Outstanding: 24.50 (millions) Market Capitalization: $230.09 (millions) Beta: -0.03 52 Week High: $45.00 52 Week Low: $7.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.21% -6.23% 12 Week -31.56% -33.23% Year To Date -69.49% -72.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 HASKINS WAY - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-695-0677 fax: - erose@lyell.com http://www.lyell.com

• General Corporate Information    Officers Lynn Seely - Chief Executive Officer and President Richard D. Klausner - Chairman Smital Shah - Chief Financial and Business Officer Mark Bachleda - Director Otis Brawley - Director Peer Information Lyell Immunopharma, Inc. (GSAC) Lyell Immunopharma, Inc. (CASIF) Lyell Immunopharma, Inc. (ALCD.) Lyell Immunopharma, Inc. (OMNN) Lyell Immunopharma, Inc. (CGPI.) Lyell Immunopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 55083R203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 24.50 Most Recent Split Date: 6.00 (0.05:1) Beta: -0.03 Market Capitalization: $230.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 40.11% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.98 Price/Cash Flow: - Price / Sales: 8,521.95 EPS Growth vs. Year Ago Period: 33.56% vs. Previous Quarter: -74.55% Sales Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: 100.00% ROE 09/30/26 - - 06/30/26 - -91.62 03/31/26 - -85.71 ROA 09/30/26 - - 06/30/26 - -70.50 03/31/26 - -66.41 Current Ratio 09/30/26 - - 06/30/26 - 5.36 03/31/26 - 7.23 Quick Ratio 09/30/26 - - 06/30/26 - 5.36 03/31/26 - 7.23 Operating Margin 09/30/26 - - 06/30/26 - -920,285.25 03/31/26 - -794,858.12 Net Margin 09/30/26 - - 06/30/26 - -920,285.25 03/31/26 - -794,858.12 Pre-Tax Margin 09/30/26 - - 06/30/26 - -920,285.19 03/31/26 - -794,858.06 Book Value 09/30/26 - - 06/30/26 - 9.54 03/31/26 - 11.73 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©